Lindor, Keith D.

The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study

Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 2,890

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 1,131

Primary biliary cirrhosis # †

Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 1,099

Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis

Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 1,085

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases

Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 913

Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy

Ghazale, A., Chari, S. T., Zhang, L., Smyrk, T. C., Takahashi, N., Levy, M. J., Topazian, M. D., Clain, J. E., Pearson, R. K., Petersen, B. T., et al. (2008) · Gastroenterology

IgG4-Related and Inflammatory DiseasesLiver Diseases and Immunity

Cited by 890

Primary biliary cirrhosis

Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 735

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 727

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 720

Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview‐based study of 1032 patients

Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 621

Ursodiol for Primary Sclerosing Cholangitis

Lindor, K. D. (1997) · New England Journal of Medicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 598

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid

Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 576

Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis

Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 533

ACG clinical guideline: primary sclerosing cholangitis

Lindor, K. D., Kowdley, K. V., & Harrison, E. M. (2015) · American Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 524

Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study

Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 498

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 487

Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy

Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 441

Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis

Charatcharoenwitthaya, P., Enders, F. B., Halling, K. C., & Lindor, K. D. (2008) · Hepatology

Cholangiocarcinoma and Gallbladder Cancer StudiesLiver Diseases and Immunity

Cited by 393

Epidemiology and natural history of primary biliary cirrhosis in a U.S. community

Kim, W. R., Lindor, K. D., Locke, G. R., Therneau, T. M., Homburger, H. A., Batts, K. P., Yawn, B. P., Petz, J. L., Melton, L. J., & Dickson, E. R. (2000) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 349

The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis

Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences

Cholangiocarcinoma and Gallbladder Cancer StudiesLiver Diseases and Immunity

Cited by 339

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

Harms, M. H., van Buuren, H. R., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Hirschfield, G. M., Parés, A., Floreani, A., Mayo, M. J., et al. (2019) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 289

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study

Tabibian, J. H., Weeding, E., Jorgensen, R. A., Petz, J. L., Keach, J. C., Talwalkar, J. A., & Lindor, K. D. (2013) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 267

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 242

Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 234